Test Type: 26-WEEK

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

TEF TRANSGENICS (TCDD)

CAS Number: 1746-01-6 **Route: SKIN APPLICATION**

Species/Strain: MICE/TG.AC HEMI

Date Report Regsted: 06/14/2006

Time Report Regsted: 13:12:56 First Dose M/F: NA / 04/21/03

Lab: BAT

C Number: C20201A

Lock Date: 07/24/2004

Cage Range: ALL

Date Range: ALL

Reasons For Removal: ALL

Removal Date Range: ALL

Treatment Groups: Include 001 0 NG/KG Include 002 121 NG/KG Include 003 760 NG/KG

Test Type: 26-WEEK

Route: SKIN APPLICATION

Species/Strain: MICE/TG.AC HEMI

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

TEF TRANSGENICS (TCDD)

CAS Number: 1746-01-6

Date Report Reqsted: 06/14/2006

Time Report Reqsted: 13:12:56 First Dose M/F: NA / 04/21/03

Lab: BAT

20 1	20	20	
1	20	20	
		20	
	_	_	
	6	8	
2	2	1	
17	12	11	
		•	
(20)	(20)	(20)	
1	,	,	
1 [1.0]	4 [1.0]	8 [1.0]	
1 [1.0]	4 [1.3]	7 [1.3]	
1			
19 [1.2]	19 [1.2]		
		2 [2.0]	
10 [1.0]	9 [1.0]		
(1)	(0)		
(I) 1 [3 O]	(0)		
	(0)	1 [3.0] (0)	
(1) (6)	(4)	(5)	
(0)	(7)		
(1)	(0)		
	(-)		
	(6)	(2)	
, <i>'</i>	1	. ,	
	(20) 1 1 [1.0] 1 [1.0]	(20) (20) 1 1 [1.0] 4 [1.0] 1 [1.0] 4 [1.3] 1 19 [1.2] 19 [1.2] 7 [1.6] 9 [1.4] 10 [1.0] 9 [1.0] (1) (0) 1 [3.0] (1) (0) (6) (4) (1) (0) 1 [2.0] (6) (6)	(20) (20) (20) (20) 1

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: 26-WEEK

Route: SKIN APPLICATION

Species/Strain: MICE/TG.AC HEMI

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

TEF TRANSGENICS (TCDD)

CAS Number: 1746-01-6

Date Report Reqsted: 06/14/2006

Time Report Reqsted: 13:12:56 First Dose M/F: NA / 04/21/03

Lab: BAT

TGAC (FVB/N) HEMIZYGOUS MICE FEMALE	0 NG/KG	121 NG/KG	760 NG/KG	
Inflammation, Chronic Active Thrombosis		1 [3.0]	1 [2.0] 1 [3.0]	
ENDOCRINE SYSTEM				
None				
GENERAL BODY SYSTEM				
None				
GENITAL SYSTEM				
None				
HEMATOPOIETIC SYSTEM				
Lymph Node Lymph Node, Mandibular Hyperplasia, Lymphoid Spleen Hematopoietic Cell Proliferation Myelodysplasia Thymus Atrophy	(0) (0) (20) 3 [1.3] (20) 3 [2.7]	(0) (1) 1 [2.0] (20) 9 [1.7] (19) 3 [3.0]	(1) (2) 2 [2.5] (20) 11 [2.3] 2 [2.0] (19) 5 [2.4]	
INTEGUMENTARY SYSTEM				
Skin Cyst Epithelial Inclusion Fibrosis	(4) 1 [2.0]	(2)	(6) 1	
Hyperplasia, Squamous Inflammation, Chronic Active Ulcer	4 [1.8] 3 [1.3] 1 [1.0]	1 [2.0]	4 [2.5]	
Skin, Control Dermis Inflammation, Chronic Active Skin, Control Epidermis Hyperkeratosis	(20) (20)	(20) (20) 1 [1.0]	(20) 4 [1.0] (20)	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: 26-WEEK

Route: SKIN APPLICATION

Species/Strain: MICE/TG.AC HEMI

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

TEF TRANSGENICS (TCDD)

CAS Number: 1746-01-6

Date Report Reqsted: 06/14/2006

Time Report Reqsted: 13:12:56 First Dose M/F: NA / 04/21/03

Lab: BAT

TGAC (FVB/N) HEMIZYGOUS MICE FEMALE	0 NG/KG	121 NG/KG	760 NG/KG	
Hyperplasia, Squamous		1 [1.0]		
Skin, Site Of Application	(20)	(20)	(20)	
Fibrosis	1 [2.0]	1 [2.0]	, ,	
Hyperkeratosis			1 [1.0]	
Hyperplasia, Squamous	1 [3.0]	13 [3.2]	14 [2.5]	
Inflammation, Chronic Active	2 [1.0]	17 [2.2]	20 [2.5]	
Skin, Soa No Mass	(20)	(20)	(17)	
Hyperplasia, Mast Cell		1 [2.0]		
Hyperplasia, Squamous	1 [1.0]	6 [1.2]	10 [1.3]	
Inflammation, Granulomatous			1 [1.0]	
Inflammation, Chronic Active	3 [1.0]	8 [1.3]	13 [1.5]	
Ulcer	- ·	1 [1.0]		

MUSCULOSKELETAL SYSTEM

None

NERVOUS SYSTEM

None

RESPIRATORY SYSTEM

Lung	(20)	(20)	(20)
Alveolar Epithelium, Hyperplasia			1 [2.0]
Alveolus, Infiltration Cellular, Histiocyte		2 [1.0]	1 [3.0]
Bronchiole, Inflammation			2 [1.0]
Interstitium, Inflammation	1 [1.0]	1 [2.0]	3 [2.0]
Perivascular, Infiltration Cellular, Mixed Cell		1 [1.0]	
Perivascular, Inflammation	2 [1.0]	2 [1.0]	2 [1.0]
Serosa, Inflammation, Chronic Active	7 [1.0]	4 [1.0]	4 [1.8]

SPECIAL SENSES SYSTEM

None

URINARY SYSTEM

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: 26-WEEK

Route: SKIN APPLICATION

Species/Strain: MICE/TG.AC HEMI

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

TEF TRANSGENICS (TCDD)

CAS Number: 1746-01-6

Date Report Reqsted: 06/14/2006

Time Report Reqsted: 13:12:56 First Dose M/F: NA / 04/21/03

Lab: BAT

TGAC (FVB/N) HEMIZYGOUS MICE FEMALE	0 NG/KG	121 NG/KG	760 NG/KG
Kidney Renal Tubule, Dilatation Renal Tubule, Vacuolization Cytoplasmic	(0)	(0)	(2) 1 [2.0] 1 [1.0]

*** END OF REPORT ***

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)